Biochemical evidence for expression of a semi-allogeneic, H-2 antigen by a murine adenocarcinoma
- PMID: 6847892
Biochemical evidence for expression of a semi-allogeneic, H-2 antigen by a murine adenocarcinoma
Abstract
LT-85 is an alveolegenic adenocarcinoma induced in mutant C3HfB/HeN (C3Hf) mice. This tumor, however, grows preferentially in allogeneic, wild-type C3H/HeN (C3H) mice. The tumor-associated transplantation antigen has been mapped to the K end of the major histocompatibility complex. H-2K antigens were isolated from detergent extracts of LT-85 cells by immunoprecipitation with monoclonal antibody. The tryptic peptides of these antigens were compared, by using high-pressure liquid chromatography, with the tryptic peptides of H-2K antigens isolated from syngeneic mutant C3Hf and ancestral wild-type C3H spleen cells. We found that the H-2K antigens of the LT-85 tumor cells were very similar to, but distinct from, those present on syngeneic C3Hf lymphoid cells. We also found, however, that the H-2K antigens of LT-85 tumor cells were clearly different from the H-2K antigens of allogeneic C3H spleen cells. The H-2K antigens of LT-85 cells are therefore foreign to syngeneic C3Hf cells, but do not represent expression by the tumor cells of the allogeneic H-2K antigens expressed by normal C3H cells. Furthermore, the nature of the differences observed between the H-2K antigens of LT-85 cells and C3Hf and C3H spleen cells strongly suggests that the structure of the H-2K molecule of LT-85 cells is identical in some regions to the H-2K molecule of C3Hf cells, and in other regions to the H-2K molecule of C3H cells.
Similar articles
-
Biochemical comparison of MHC antigens isolated from mutant C3HfB/HeN and parent C3H/HeN mice.J Immunol. 1982 May;128(5):2116-20. J Immunol. 1982. PMID: 7061856
-
Soluble factors produced during an immune response regulate Ia antigen expression by murine adenocarcinoma and fibrosarcoma cells.J Immunol. 1984 May;132(5):2649-57. J Immunol. 1984. PMID: 6201554
-
Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.Cancer Res. 1995 May 1;55(9):1911-6. Cancer Res. 1995. PMID: 7728758
-
Somatic cell variants of the murine major histocompatibility complex.Immunol Res. 1987;6(1-2):133-44. doi: 10.1007/BF02918109. Immunol Res. 1987. PMID: 3305735 Review. No abstract available.
-
Immunogenicity of tumors alkylated with cyclohexyl-, benzyl-. or 2,4-dinitrophenylmethacrylate.Ann N Y Acad Sci. 1976;277(00):412-27. doi: 10.1111/j.1749-6632.1976.tb41718.x. Ann N Y Acad Sci. 1976. PMID: 826206 Review. No abstract available.
Cited by
-
Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule.Proc Natl Acad Sci U S A. 1985 Aug;82(15):5140-4. doi: 10.1073/pnas.82.15.5140. Proc Natl Acad Sci U S A. 1985. PMID: 3860848 Free PMC article.
-
Subline divergence within L.C. Strong's C3H and CBA inbred mouse strains. A review.Immunogenetics. 1985;21(5):407-28. doi: 10.1007/BF00430926. Immunogenetics. 1985. PMID: 2987113 Review. No abstract available.